Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age

Citation
Pj. Snyder et al., Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age, AM J MED, 111(4), 2001, pp. 255-260
Citations number
27
Categorie Soggetti
General & Internal Medicine","Medical Research General Topics
Journal title
AMERICAN JOURNAL OF MEDICINE
ISSN journal
00029343 → ACNP
Volume
111
Issue
4
Year of publication
2001
Pages
255 - 260
Database
ISI
SICI code
0002-9343(200109)111:4<255:EOTTTO>2.0.ZU;2-H
Abstract
PURPOSE: Because the effects of androgen replacement on lipoprotein levels are uncertain, we sought to determine the effect of transdermal testosteron e treatment on serum lipid and apolipoprotein levels in elderly men. SUBJECTS AND METHODS: One hundred and eight healthy men more than 65 years of age who had serum testosterone concentrations >1 SD below the mean for y oung men were randomly assigned to receive either testosterone (54 men; 6 m g/day) or placebo (54 men) transdermally in a double-blind fashion for 36 m onths. Serum concentrations of lipids and apolipoproteins were measured, an d cardiovascular events recorded. RESULTS: Serum total cholesterol concentrations decreased in both the testo sterone-treated men and placebo-treated men, but the 3-year mean ( SD) decr eases in the two groups (testosterone treated, -17 +/- 29 mg/dL; placebo tr eated, -12 +/- 38 mg/dL) were not significantly different from each other ( P = 0.4). Similarly, serum low-density lipoprotein (LDL) cholesterol levels decreased in both treatment groups, but the decreases in the two groups (t estosterone treated, - 6-24 mg/dL; placebo treated, - 16 +/- 33 mg/dL) were similar (P = 1.0). Levels of high-density lipoprotein (HDL) cholesterol, t riglycerides, and apolipoproteins A-I and B did not change. Lipoprotein(a) levels increased in both groups by similar amounts (testosterone treated, 3 +/- 9 mg/dL; placebo treated, 4 +/- 6 mg/dL; P = 1.0). The number of cardi ovascular events was small and did not differ significantly between the tes tosterone-treated men (9 events) and the placebo-treated men (5 events) dur ing the 3-year study (relative risk = 1.8; 95% confidence interval: 0.7 to 5.0). CONCLUSIONS: As compared with placebo, transdermal testosterone treatment o f healthy elderly men for 3 years did not affect any of the lipid or apolip oprotein parameters that we measured. The effect of testosterone treatment on cardiovascular events was unclear, because the number of events was smal l.